Patient Support

How to Order SUPPRELIN® LA Patient Education Materials

To receive printed SUPPRELIN LA patient education materials, please select the particular materials you need. Then provide your contact information below and click "SUBMIT."

 

Patient Brochures:
Patient Brochures (bundle of 25)
Spanish Brochures:
Spanish Patient Brochure (bundle of 25)
Name:*
Institution:*
Address:*
City:*
State:*
Zip Code:*
Telephone:*
E-mail:*
* required Submit   Cancel      

SUPPRELIN LA Reimbursement Support

Endo Pharmaceuticals, the makers of SUPPRELIN LA, have established the SUPPRELIN LA Support Center-providing confidential reimbursement services.

 

Program specialists are available toll-free at 1-855-270-0123, Monday through Friday, 8 a.m. to 8 p.m. EST.

 

The SUPPRELIN LA Support Center can also work with patients and families to organize and coordinate the services needed to initiate SUPPRELIN LA. Qualified SUPPRELIN LA patients may obtain financial assistance through SHARES, a financial support program that includes co-pay assistance for eligible families. Restrictions may apply.

 

Next: SUPPRELIN® LA Reimbursement

Indication

SUPPRELIN® LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP).

Important Safety Information

  • SUPPRELIN LA is contraindicated in women who are or may become pregnant, and in patients who are hypersensitive to GnRH or GnRH agonist analogs. Safety and effectiveness in pediatric patients under the age of 2 years has not been established.

  • SUPPRELIN LA, like other GnRH agonists, initially causes a transient increase in serum concentrations of estradiol in females and testosterone in both sexes during the first week of treatment, with worsening or onset of new symptoms during this period. Within 4 weeks of therapy, gonadal steroid suppression occurs and manifestations of puberty decrease.

  • Implant insertion and removal is a surgical procedure and should utilize aseptic technique. Careful adherence to the recommended insertion and removal procedures is recommended. On occasion, localizing and/or removal of implant products have been difficult and imaging techniques were used, including ultrasound, CT, or MRI (this implant is not radiopaque).

  • Rare events of spontaneous extrusion have been observed in clinical trials.

  • LH, FSH and estradiol or testosterone should be monitored at 1 month post implantation then every 6 months. Every 6-12 months, height and bone age should also be assessed.

  • In clinical trials, the most common adverse reactions involved the implant site and included bruising, pain, soreness, erythema and swelling.

Please see the accompanying full Prescribing Information.